703 related articles for article (PubMed ID: 16234499)
1. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
[TBL] [Abstract][Full Text] [Related]
3. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.
Huo D; Senie RT; Daly M; Buys SS; Cummings S; Ogutha J; Hope K; Olopade OI
J Clin Oncol; 2009 Mar; 27(8):1184-90. PubMed ID: 19188678
[TBL] [Abstract][Full Text] [Related]
4. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
Hall MJ; Reid JE; Burbidge LA; Pruss D; Deffenbaugh AM; Frye C; Wenstrup RJ; Ward BE; Scholl TA; Noll WW
Cancer; 2009 May; 115(10):2222-33. PubMed ID: 19241424
[TBL] [Abstract][Full Text] [Related]
6. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Kurian AW; Gong GD; John EM; Miron A; Felberg A; Phipps AI; West DW; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1084-91. PubMed ID: 19336551
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients.
Pal T; Permuth-Wey J; Holtje T; Sutphen R
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1794-9. PubMed ID: 15533909
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
9. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
Armstrong K; Micco E; Carney A; Stopfer J; Putt M
JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
[TBL] [Abstract][Full Text] [Related]
10. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women.
Haffty BG; Silber A; Matloff E; Chung J; Lannin D
J Med Genet; 2006 Feb; 43(2):133-7. PubMed ID: 15983021
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
[TBL] [Abstract][Full Text] [Related]
12. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
Schubert EL; Lee MK; Mefford HC; Argonza RH; Morrow JE; Hull J; Dann JL; King MC
Am J Hum Genet; 1997 May; 60(5):1031-40. PubMed ID: 9150150
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Jackson SA; Davis AA; Li J; Yi N; McCormick SR; Grant C; Fallen T; Crawford B; Loranger K; Litton J; Arun B; Vande Wydeven K; Sidani A; Farmer K; Sanders M; Hoskins K; Nussbaum R; Esserman L; Garber JE; Kaklamani VG;
Cancer; 2014 May; 120(10):1557-64. PubMed ID: 24522996
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
[TBL] [Abstract][Full Text] [Related]
16. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
[TBL] [Abstract][Full Text] [Related]
17. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
Palma MD; Domchek SM; Stopfer J; Erlichman J; Siegfried JD; Tigges-Cardwell J; Mason BA; Rebbeck TR; Nathanson KL
Cancer Res; 2008 Sep; 68(17):7006-14. PubMed ID: 18703817
[TBL] [Abstract][Full Text] [Related]
18. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
Newman B; Mu H; Butler LM; Millikan RC; Moorman PG; King MC
JAMA; 1998 Mar; 279(12):915-21. PubMed ID: 9544765
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
[TBL] [Abstract][Full Text] [Related]
20. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
